| [1] |
胡夕春,王碧芸,邵志敏.2011 年《St. Gallen 早期乳腺癌初始治疗国际专家共识》与中国抗癌协会乳腺癌专业委员会指南之比较[J/CD]. 中华乳腺病杂志:电子版,2011,5(4):404-407.
|
| [2] |
Osborne CK, Pippen J, Jones SE, et al. Double-blind,randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy:results of a North American trial[J]. J Clin Oncol,2002,20(16):3386-3395.
|
| [3] |
Harvey JM, Clark GM, Osborne CK,et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer[J]. J Clin Oncol,1999,17(5):1474-1481.
|
| [4] |
Khoshnoud MR,Löfdahl B,Fohlin H,et al. Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen[J].Breast Cancer Res Treat,2011,126(2):421-430.
|
| [5] |
Hammond ME,Hayes DF,Dowsett M,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Clin Oncol,2010,28(21):2784-2795.
|
| [6] |
Fitzgibbons PL, Murphy DA, Hammond ME, et al.Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays[J]. Arch Pathol Lab Med,2010,134(6):930-935.
|
| [7] |
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen:patient-level meta-analysis of randomised trials[J]. Lancet,2011,378(9793):771-784.
|
| [8] |
Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials [J]. Cancer,2003,98(2):229-238.
|
| [9] |
Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial[J]. J Clin Oncol,2004,22(9):1605-1613.
|
| [10] |
Robertson JF,Nicholson RI,Bundred NJ,et al. Comparison of the short-term biological effects of 7 alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17 beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer [J]. Cancer Res,2001,61(18):6739-6746.
|
| [11] |
Kuter I, Gee JM, Hegg R, et al. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant:results from NEWEST, a randomized phase Ⅱ study[J].Breast Cancer Res Treat,2012,133(1):237-246.
|
| [12] |
Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study [J].J Clin Oncol,2009,27(27):4530-4535.
|
| [13] |
Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase Ⅲtrial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer[J]. J Clin Oncol,2010,28(30):4594-4600.
|
| [14] |
Robertson JF, Semiglazov V, Nemsadze G, et al. Effects of fulvestrant 250 mg in premenopausal women with oestrogen receptor-positive primary breast cancer[J]. Eur J Cancer,2007,43(1):64-70.
|
| [15] |
Young OE, Renshaw L, Macaskill EJ, et al. Effects of fulvestrant 750 mg in premenopausal women with oestrogenreceptor-positive primary breast cancer[J]. Eur J Cancer,2008,44(3):391-399.
|
| [16] |
Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer[J]. N Engl J Med,2012,367(5):435-444.
|
| [17] |
Bergh J, Jönsson PE, Lidbrink EK, et al. FACT: an openlabel randomized phase Ⅲstudy of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer[J]. J Clin Oncol,2012,30(16):1919-1925.
|
| [18] |
Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer[J]. N Engl J Med,2012,366(6):520-529.
|
| [19] |
Bachelot T,Bourgier C,Cropet C,et al. Randomized phase Ⅱtrial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study[J]. J Clin Oncol,2012,30(22):2718-2724.
|
| [20] |
Awada A, Cardoso F, Fontaine C, et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics[J]. Eur J Cancer,2008,44(1):84-91.
|
| [21] |
Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer(ABC 1) [J].Breast,2012,21(3):242-252.
|